Evidence map›Paper›PMID 34494942›Full record

ArticleVirulence2021

The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells.

Theodoros Kelesidis, Sharma Madhav, Anton Petcherski, Hugo Cristelle, Ellen O'Connor, Nan W Hultgren, Eleni Ritou, David S Williams, Orian S Shirihai, Srinivasa T Reddy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Experimental Models of COVID-19.Frontiers in cellular and infection microbiology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Theodoros KelesidisDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Sharma MadhavDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Anton PetcherskiDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Hugo CristelleDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Ellen O'ConnorMolecular Toxicology Interdepartmental Degree Program, University of California Los Angeles, United States.
Nan W HultgrenDepartment of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Eleni RitouDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
David S WilliamsDepartment of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Orian S ShirihaiDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Srinivasa T ReddyDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
UCLA MSD ProgramR25GM055052 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARBER, PAUL HENRY, HASSON, TAMA W. · 1996 to 2021
$9.2M
The role of PON2 and PON3 proteins in AtherosclerosisR01HL071776 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REDDY, SRINIVASA T. · 2003 to 2017
$4.8M
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIVR01AG059502 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI KELESIDIS, THEODOROS · 2018 to 2022
$2.0M
Weight Loss and Exercise in Frail Obese Elderly SubjectsR01AG025501 · NIA · WASHINGTON UNIVERSITY · PI VILLAREAL, DENNIS T. · 2005 to 2009
$1.7M
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017
$915k
Impact of Seasonal Variation in Hematocrit, NOx & ET-1 on Vascular ReactivityR21NR010361 · NINR · UNIVERSITY OF MISSOURI-COLUMBIA · PI WIPKE-TEVIS, DEIDRE D · 2008 to 2009
$401k
RECOMBINANT PICORNAVIRUSES AS AIDS VACCINESR21AI036178 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI ANDINO, RAUL · 2000 to 2000
$347k
Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related TendinopathyR43AG059501 · NIA · ZEN-BIO, INC. · PI BUEHRER, BENJAMIN M, LUDLOW, JOHN WILLIAM · 2018 to 2018
$222k
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIVR03AG059462 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$156k
NHLBI NIH HHS R01 HL071776NIAID NIH HHS K08 AI108272NIAID NIH HHS P30 AI028697NIAID NIH HHS R21 AI036178NIA NIH HHS R01 AG025501NIA NIH HHS R01 AG059502NIA NIH HHS R03 AG059462NIA NIH HHS R43 AG059501NIGMS NIH HHS R25 GM055052NINR NIH HHS R21 NR010361
6 · The paper itself

Abstract

An oral antiviral against SARS-CoV-2 that also attenuates inflammatory instigators of severe COVID-19 is not available to date. Herein, we show that the apoA-I mimetic peptide 4 F inhibits Spike mediated viral entry and has antiviral activity against SARS-CoV-2 in human lung epithelial Calu3 and Vero-E6 cells. In SARS-CoV-2 infected Calu3 cells, 4 F upregulated inducers of the interferon pathway such as MX-1 and Heme oxygenase 1 (HO-1) and downregulated mitochondrial reactive oxygen species (mito-ROS) and CD147, a host protein that mediates viral entry. 4 F also reduced associated cellular apoptosis and secretion of IL-6 in both SARS-CoV-2 infected Vero-E6 and Calu3 cells. Thus, 4 F attenuates

Indexed as

AnimalsAntioxidantsAntiviral AgentsApoptosisBasiginCytokinesEpithelial CellsHeparan Sulfate ProteoglycansHumansInflammationInterferonsOxidative StressPeptidesSARS-CoV-2Spike Glycoprotein, CoronavirusVirus AttachmentAntioxidantsAntiviral Agentsapolipoprotein A-I mimetic peptide 4FBasiginCytokinesHeparan Sulfate ProteoglycansInterferonsPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-24FantioxidantsantiviralsApoA-I mimetic peptidesapoptosisCOVID-19inflammationSARS-CoV-2therapeutics

Identifiers

PMID34494942
PMCPMC8437485
OpenAlexW3197875848

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.